trastuzumab deruxtecan
daiichi sankyo,astrazeneca
['mbc', 'daisy', 'tnbc']
benefit w tdx-d seen in her2 0 subgroup based on daisy study. - mpfs was 4.2 mos (n=17). will need larger studies. - 63% of tnbc have her2 0. - how do we sequence adc in #mbc as we get more data and approvals? great discussion by #asco23 
Breast Medical Oncologist @RutgersCancer @Rutgers and @RWJMS wife/mom/baker/world traveler #bcsm